Statin use and risk of breast cancer: A meta-analysis of observational studies

Breast Cancer Research and Treatment

Volumn 135, Issue 1, 2012, Pages 261-269

  Undela, Krishna ^a   Srikanth, Vallakatla ^a   Bansal, Dipika ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Breast cancer; Meta analysis; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CHRONIC DRUG ADMINISTRATION; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; PATIENT ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHOLESTEROL; COHORT STUDIES; EPIDEMIOLOGIC STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RESEARCH DESIGN; RISK;

EID: 84865144986     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2154-x     Document Type: Article

References (48)

1. World Health Organization (2011) CancerStats Cancer worldwide. http://info.cancerresearchuk.org/cancerstats/world/. Accessed 7 February 2011
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
3. Lamb E (2009) Top 200 drugs of 2008. http://www.pharmacytimes.com/issue/ pharmacy/2009/2009-05/RxFocusTop200Drugs-0509. Accessed 7 February 2011
4. Mandal CC, Ghosh-Choudhury N, Yoneda T, Choudhury GG (2011) Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem 286:11314-11327
5. Ghosh-Choudhury N, Mandal CC, Ghosh Choudhury G (2010) Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal 22:749-758
6. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71:1763-1771
7. Vinogradova Y, Coupland C, Hippisley-Cox J (2011) Exposure to statins' and risk of common cancers: a series of nested case-control studies. BMC Cancer 11:409
8. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-1630 (Pubitemid 35379733)
9. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364:771-777 (Pubitemid 39165096)
10. Blais L, Desgagné A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160:2363-2368
11. Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, Stone KL, Cummings SR, Bauer DC (2003) Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 12:749-756 (Pubitemid 37361917)
12. Lovastatin Study Groups I through IV (1993) Lovastatin 5-year safety and efficacy study. Arch Intern Med 153:1079-1087
13. Beck P, Wysowski DK, Downey W, Butler-Jones D (2003) Statin use and the risk of breast cancer. J Clin Epidemiol 56:280-285 (Pubitemid 36513491)
14. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ (2004) The risk of cancer in users of statins'. J Clin Oncol 22:2388-2394 (Pubitemid 41115396)
15. Kaye JA, Jick H (2004) Statin use and cancer risk in the general practice research database. Br J Cancer 90:635-637 (Pubitemid 38297203)
16. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sorensen HT, Olsen JH (2005) Cancer risk among statin users: a population-based cohort study. Int J Cancer 114:643-647 (Pubitemid 40349625)
17. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR (2004) The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 100:2308-2316 (Pubitemid 38657877)
18. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2005) Use of statins' and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23:8606-8612 (Pubitemid 46211502)
19. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE (2005) Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 165:2264-2271 (Pubitemid 41549923)
20. Kochhar R, Khurana V, Bejjanki H, Caldito G, Fort C (2005) Statins' reduce breast cancer risk: a case control study in US female veterans. J Clin Oncol 23(Suppl 1):16S, Abstract 514
21. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski RT (2006) Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 98:700-707 (Pubitemid 43821787)
22. Dumasia L, Lobocki C, Couturier A, Lebeis C, Derlichman A (2006) Use of statins' and breast carcinoma: a case-control study. J Clin Oncol 24(Suppl 20):18S, Abstract 592
23. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71:1763-1771
24. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR (2007) Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 16:416-421 (Pubitemid 46548643)
25. Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18:213-219
26. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S (2008) Effect of statins' on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 67:99-109
27. Eaton M, Eklof J, Beal JR, Sahmoun AE (2009) Statins' and breast cancer in postmenopausal women without hormone therapy. Anticancer Res 29:5143-5148
28. Hippisley-Cox J, Coupland C (2010) Unintended effects of statins' in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340:c2197
29. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S (2007) Statins' and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115:27-33 (Pubitemid 46058608)
30. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP, Habel LA (2008) Screening statins' for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17:27-36 (Pubitemid 351166615)
31. Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Egan KM (2008) Statin use and risk of breast cancer. Cancer 112:27-33
32. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J (2010) Incidence of cancer and statin usage record linkage study. Int J Cancer 126:279-284
33. Woditschka S, Habel LA, Udaltsova N, Friedman GD, Sieh W (2010) Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 19:2479-2487
34. Vinogradova Y, Coupland C, Hippisley-Cox J (2011) Exposure to statins' and risk of common cancers: a series of nested case-control studies. BMC Cancer 11:409
35. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S (2002) Statin use and the risk of breast and prostate cancer. Epidemiology 13:262-267 (Pubitemid 34415845)
36. Kaye JA, Meier CR, Walker AM, Jick H (2002) Statin use, hyperlipidaemia, and the risk of breast cancer. Br J Cancer 86:1436-1439 (Pubitemid 34548066)
37. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101
38. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634 (Pubitemid 27387172)
39. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560 (Pubitemid 37088507)
40. Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326:219 (Pubitemid 36143396)
41. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283:2008-2012 (Pubitemid 30214957)
42. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109:573-579 (Pubitemid 351698864)
43. Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W (2011) Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins'. Cancer Invest 29:585-593
44. Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508-519 (Pubitemid 34460459)
45. Chan KK, Oza AM, Siu LL (2003) The statins' as anticancer agents. Clin Cancer Res 9:10-19
46. Newman TB, Hulley SB (1996) Carcinogenicity of lipid-lowering drugs. JAMA 275:55-60 (Pubitemid 26004257)
47. Rogers MJ (2000) Statins': lower lipids and better bones? Nat Med 6:21-23 (Pubitemid 30048514)
48. Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26-37 (Pubitemid 28094090)